July 26,2025

Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer's Disease

Source By:  PRNEWSWIRE
 June 13,2025

   0        7        0

TAINAN, June 13, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the launch of its global Phase II clinical trial for TML-6, a novel oral small molecule drug targeting early-stage Alzheimer's disease (AD). TML-6 combines multiple mechanisms, including anti-oxidative effects (Nrf2 activation), melioration of autophagy function (autolysosomal activation), anti-amyloid accumulation (?-amyloid clearance), and anti-inflammatory effects (through NF-?B inhibition) through autolysosome pathway in neurons and microglia to remove intraneuronal and extracellular amyloid accumulation, representing the first in human multi-target strategy for AD treatment.

The Phase I trial showed excellent safety, tolerability, and pharmacokinetics at 100–200 mg in both healthy and elderly adults. TML-6 will now advance to a Phase II 19 site trial across the United States, Sweden, and Taiwan after FDA approval. This 12-month study will enroll 210 patients with mild cognitive impairment (MCI) or mild dementia.

Primary endpoints will include neuropsychological assessments (CDR-SB, iADRS) and blood biomarkers (p-Tau 217, A?42/40, NfL, GFAP), supported by brain MRI, amyloid PET scans, and ApoE genotyping. Type C FDA consultation for phase 2 trial design has completed on 13 May 2025, with trial initiation expected in April 2026, conducted by Syneos Health CRO.

With its strong preclinical and clinical profile, TML-6 holds promise as both a monotherapy and in combination with anti-amyloid biologics, providing new hope for patients with Alzheimer's disease.

About Merry Life Biomedical Company

Merry Life Biomedical is a Taiwan-based biotechnology company focused on developing innovative therapies for neurodegenerative and age-related diseases. Leveraging advanced molecular design, pharmacological innovation, formulation optimization and global clinical development, the company is committed to addressing urgent unmet medical needs.

Media Contact

Dr. Ih-Jen Su

Merry Life Biomedical Company, Ltd.

Phone: +886-910-902-296

Email: suihjen0704@stust.edu.tw 

Logo - https://mma.prnewswire.com/media/2708243/Merry_Life_LOGO_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/merry-life-launches-global-phase-ii-trial-of-tml-6-the-first-drug-targeted-at-autolysosome-pathway-for-therapy-of-alzheimers-disease-302478755.html


About us

Leverage agile frameworks to provide a robust synopsis for high level overviews. Iterative approaches to corporate strategy foster collaborative thinking to further the overall value proposition. Organically grow the holistic world view of disruptive innovation via workplace diversity and empowerment.


CONTACT US



X

Our website uses cookies to provide your browsing experience and relavent informations.Before continuing to use our website, you agree & accept of our Cookie Policy & Privacy